DOI QR코드

DOI QR Code

Immunohistochemical Expression of B Cell Lymphoma-2 with Clinicopathological Correlation in Triple Negative Breast Cancers in Northern Pakistan

  • Zubair, Muhammad (Registrar Histopathology, Armed Forces institute of Pathology) ;
  • Hashmi, Shoaib Naiyar (Registrar Histopathology, Armed Forces institute of Pathology) ;
  • Afzal, Saeed (Registrar Histopathology, Armed Forces institute of Pathology) ;
  • Muhammad, Iqbal (Registrar Histopathology, Armed Forces institute of Pathology) ;
  • Din, Hafeez Ud (Registrar Histopathology, Armed Forces institute of Pathology) ;
  • Ahmed, Rabia (Registrar Histopathology, Armed Forces institute of Pathology)
  • Published : 2016.07.01

Abstract

Background: Triple negative breast cancers (TNBCs) are high grade aggressive tumors generally with a poor prognosis, not responding to hormonal and anti Her2 Neu therapy. Expression of the antiapoptotic B cell lymphoma 2 gene (Bcl-2) is associated with low grade, slowly proliferating hormone receptor positive tumors with improved survival. Anti Bcl2 agents can be used as alternative targeted therapy in triple negative cancers. Materials and Methods: The objective of this study was to determine the immunohistochemical expression of Bcl2 in triple negative breast cancers and any correlation with clinicopathological variables in Northern Pakistan. Results: All 52 patients were females, aged between 28 and 80 years(average $48.0{\pm}12.1$). 28 cases (53.8%) were positive for Bcl2, this being associated with low grade invasive ductal carcinomas, lymph node metastasis and lymphovascular invasion. Conclusions: Bcl-2 may be an important prognostic factor and its expression might be used for targeted therapy using Anti Bcl2 drugs.

Keywords

Triple negative breast cancers;B cell lymphoma gene 2;lymphovascular invasion

References

  1. Abd El-Hafez, Shawky Mohamed Ael-A, Elesawy BH (2013). Bcl-2 Expression among Triple Negative and Non-Triple Negative Breast Cancers. Asian Pac J Cancer Prev, 14, 1037-41. https://doi.org/10.7314/APJCP.2013.14.2.1037
  2. Badve S, Dabbs DJ, Schnitt SJ, et al (2011). Basal-like and triplenegative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern Pathol, 24, 157-67. https://doi.org/10.1038/modpathol.2010.200
  3. Bertucci F, Finetti P, Cervera N, et al (2008). How basal are triple-negative breast cancers? Int J Cancer, 123, 236-240. https://doi.org/10.1002/ijc.23518
  4. Callagy G, Cattaneo E, Daigo Y, et al (2003). Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol, 12, 27-34. https://doi.org/10.1097/00019606-200303000-00004
  5. Formenti SC, Arslan AA, Love SM (2012). Global breast cancer: The lessons to bring home. Int J Breast Cancer, 2012, 249501.
  6. Fulford LG, Reis-Filho JS, Ryder K, et al (2007). Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res, 9, 4.
  7. Hicks DG, Short SM, Prescott NL, et al (2006). Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5 / 6, and overexpress HER2 or EGFR. Am J Surg Pathol, 30, 1097-104.
  8. Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE (2010). Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. a SEER analysis. BMC Cancer, 10, 191. https://doi.org/10.1186/1471-2407-10-191
  9. Oakes SR, Vaillant F, Lim E, et al (2012). Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA, 109, 2766-71. https://doi.org/10.1073/pnas.1104778108
  10. Ontilio AA, Engel JM, Greenlee RT, Mukesh BN. (2009). Breast Cancer Subtypes Based on ER/PR and Her2 expression: Comparison of clinicopathological features and survival. Clin Med Res, 7, 4-13. https://doi.org/10.3121/cmr.2008.825
  11. Pala EE, Bayol U, Cumurcu S, et al (2012). Immunohistochemical Characteristics of Triple Negative/Basal-like Breast Cancer. Turk Patoloji Derg, 28, 238-44.
  12. Peppercorn J, Perou CM, Carey LA (2008). Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest, 26, 1. https://doi.org/10.1080/07357900701784238
  13. Reis-Filho JS, Tutt AN (2008). Triple negative tumours: a critical review. Histopathol, 52, 108-18.
  14. Ryu DW, Lee CH (2012). Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death. J Korean Surg Soc, 4, 187-95.
  15. Sezgin Alikanoglu A, Yildirim M, Suren D, et al (2014). Expression of cyclooxygenase-2 and Bcl-2 in breast cancer and their relationship with triple-negative disease. J BUON, 2, 430-4.
  16. Shafqat G, Masror I, Rehan M, Afzal S, Agha A (2011). Dynamic contrast enhanced MRI breast for lesion detection and characterization with histopathological co relation: Preliminary experience at tertiary care hospital. J Pak Med Assoc, 61, 3.
  17. Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O (2012). Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple negative and non triple negative" tumors. Hum Pathol, 1, 23-30.